Fate Therapeutics (FATE) Tops Q3 EPS by 6c

Fate Therapeutics (NASDAQ: FATE) reported Q3 EPS of ($0.24), $0.06 better than the analyst estimate of ($0.30). Revenue for the quarter came in at $1 million versus the consensus estimate of $430 thousand.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Aspire Biopharma to acquire automotive supplier for $30 million
• Investing.com’s stocks of the week